Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

导出原文传递

翻译打印收藏纠错

作者： D'Angelo, Sandra P. ^[1] ; Mahoney, Michelle R. ^[2] ; Van Tine, Brian A. ^[3] ; Atkins, James ^[4] ; Milhem, Mohammed M. ^[5] ; Jahagirdar, Balkrishna N. ^[6] ; Antonescu, Cristina R. ^[7] ; Horvath, Elise ^[8] ; Tap, William D. ^[9] ; Schwartz, Gary K. ; Streicher, Howard

作者单位： Columbia Univ, Sch Med, Herbert Irving Canc Ctr, New York, NY USA ^[1] Southeast Clin Oncol Res Consortium NCORP, Winston Salem, NC USA ^[2] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA ^[3] Astellas, Northbrook, IL USA ^[4] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA USA ^[5] Washington Univ St Louis, Sch Med, St Louis, MO USA ^[6] Mayo Clin, Alliance Stat & Data Ctr, Rochester, MN USA ^[7] NCI, Canc Therapy Evaluat Program, Invest Drug Branch, Bethesda, MD 20892 USA ^[8] Reg Hosp, Canc Care Ctr, St Paul, MN USA ^[9]

发布时间 2018-12-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

The lancet oncology

2018年19卷3期

416-426页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

The lancet oncology

相似文献

The lancet oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

The lancet oncology

相似文献

The lancet oncology

相关期刊

检索历史清除